Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Developments And Opportunities Across 2026–2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market From 2026 To 2030?
The primary progressive multiple sclerosis (ppms) treatment market size has seen swift expansion in recent years. It is anticipated to increase from $1.16 billion in 2025 to $1.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. This historical growth can be linked to factors including restricted treatment options for ppms, a reliance on corticosteroids for managing symptoms, limited patient awareness of ppms, an underdeveloped hospital pharmacy infrastructure, and the slow integration of immunosuppressants.
The primary progressive multiple sclerosis (ppms) treatment market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. Factors contributing to this projected growth include the introduction of targeted monoclonal antibodies, a rise in research and development efforts for neurodegenerative disorders, the expansion of hospital and online pharmacy channels, an increase in regulatory approvals for new treatments, and enhanced patient awareness along with early diagnosis initiatives. Key trends anticipated during this period encompass the growing acceptance of monoclonal antibodies for PPMS, a heightened emphasis on symptom control and improving patients’ quality of life, a rising preference for intravenous drug delivery, the enlargement of hospital and specialty pharmacy avenues, and the innovation of new therapeutics and combined treatment approaches.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp
What Factors Are Contributing To The Growth Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
The future expansion of the primary progressive multiple sclerosis (PPMS) treatment market is anticipated to be fueled by the increasing need for efficacious therapies. Such therapies represent medical interventions designed to alleviate symptoms, enhance patient results, or eradicate a disease or ailment. This escalating requirement for effective treatments primarily stems from the growing incidence of chronic and intricate health issues, which necessitate ongoing management and sophisticated therapeutic approaches to elevate patient outcomes and living standards. For primary progressive multiple sclerosis (PPMS), effective treatments are instrumental in decelerating disease progression by addressing inflammation and safeguarding neurological function. This, in turn, leads to an improved long-term quality of life, diminished disability progression, and a greater capacity for patients to independently and stably conduct daily activities. As an illustration, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, reported that gene therapies in Phase III clinical trials totaled 33 Phase III gene therapy trials in 2023, reflecting a 10% rise from 2022 and marking the initial quarterly increase since Q3 2022. Consequently, the rising demand for effective treatments is a key driver for the growth of the primary progressive multiple sclerosis (PPMS) treatment market.
How Are Segments Identified Within The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segment Framework?
The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab
2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone
4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone
What Emerging Trends Are Seen In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
Leading companies within the primary progressive multiple sclerosis (PPMS) treatment market are intensifying their efforts to develop cutting-edge formulations, such as monoclonal antibody drugs, to improve multiple sclerosis therapy. A monoclonal antibody drug works in multiple sclerosis by targeting specific immune cells or proteins that contribute to inflammation and nerve damage, thereby decreasing disease activity and slowing symptom progression. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, for the treatment of multiple sclerosis (MS) in India. Ocrevus is significant as the first and only approved disease-modifying therapy (DMT) available in the country for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). The medication operates by targeting CD20-positive B cells, an immune cell type involved in the aberrant immune response observed in MS. It is administered via a twice-yearly intravenous infusion lasting only two hours, offering patients a more convenient and effective treatment choice.
Who Are The Companies Competing Within The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA
Get The Full Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report:
Which Geographic Region Dominates The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company
Multiple Sclerosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report
Atherosclerosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
Focal Segmental Glomerulosclerosis Drugs Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
